A UK vac­cine cen­ter is on the mar­ket and field­ing of­fers from man­u­fac­tur­ing gi­ants

4 years ago
Manufacturing

One work­er at a Lat­vian man­u­fac­tur­er is dead af­ter a fire breaks out at fa­cil­i­ty

4 years ago
Manufacturing

British CD­MO Ster­ling part­ners up on low-cost man­u­fac­tur­ing of mol­nupi­ravir

4 years ago
Coronavirus
Manufacturing

Sam­sung Bi­o­log­ics takes on man­u­fac­tur­ing du­ties for Green­Light's Covid-19 vac­cine

4 years ago
Coronavirus
Manufacturing

Fu­ji­film Diosynth dumps an­oth­er $454M in­to its sup­ply chain, this time at a fa­cil­i­ty in the UK

4 years ago
Manufacturing

Covid-19 man­u­fac­tur­ing roundup: 3 com­pa­nies to col­lab­o­rate on mR­NA vac­cine; Omi­cron-fo­cused vac­cine could be on the ...

4 years ago
Coronavirus
Manufacturing

Ex-No­var­tis busi­ness head hops over to a gene ther­a­py start­up — and she's reeled in $80M for a dash to the clin­ic

4 years ago
Financing
Startups

Am­gen's Ote­zla notch­es an­oth­er PhI­II win; Califf earns ad­vo­ca­cy group­s' stamp of ap­proval

4 years ago
News Briefing

With gener­ic com­pe­ti­tion heat­ing up, Vas Narasimhan out­lines No­var­tis' growth plans at R&D day

4 years ago
R&D

A Seat­tle biotech of­floads lead eye drug in deal val­ued at $1B+ as it re­fo­cus­es on emerg­ing pipeline

4 years ago
Deals

A qui­et Czech biotech bags $315M to dri­ve its blos­som­ing can­cer pipeline through the clin­ic

4 years ago
Financing

As Omi­cron spread looms, oral an­tivi­rals ap­pear to be one of the best de­fens­es — now we just need more

4 years ago
Pharma
Coronavirus

Can the an­ti­body-drug con­ju­gate mod­el work for NK cells? Ace­po­dia loads up with an­oth­er $109M to find out

4 years ago
Financing

In­mate who posed as Ab­b­Vie pur­chas­ing of­fi­cer in $3M scam sen­tenced to 7 more years of prison

4 years ago
People

Watch out, Roche: No­var­tis inks $1.5B deal to chase down promi­nent Parkin­son’s tar­get

4 years ago
Deals

Am­gen halts some drug dis­counts for safe­ty net hos­pi­tals as SCO­TUS takes on 340B case

4 years ago
Pharma

Bob Nelsen woos John Maraganore to his first VC post af­ter re­tir­ing from Al­ny­lam

4 years ago
People

An­oth­er epigenome edit­ing start­up launch­es from a pair of the field’s long­time lead­ers

4 years ago
Startups
Cell/Gene Tx

Glax­o­SmithK­line, Ox­ford un­veil new part­ner­ship pit­ting buzzy R&D ad­vances against neu­ro­log­i­cal dis­ease

4 years ago
Deals
Discovery

With on­ly burns to show in gene ther­a­py, Astel­las inks deal with AAV spe­cial­ist Dyno in push for a bet­ter cap­sid

4 years ago
Deals
Cell/Gene Tx

J&J and Sanofi's mul­ti­ple myelo­ma tit-for-tat con­tin­ues, as sub­cu­ta­neous Darza­lex wins com­bo ap­proval

4 years ago
FDA+

As first Omi­cron case in US crops up, re­searchers won­der: Which an­ti­bod­ies, vac­cines will hold up?

4 years ago
Coronavirus

Glax­o­SmithK­line's friend­ly ‘shark tank’ crowd­sources ideas for mul­ti­ple myelo­ma, kicks off big­ger push

4 years ago
Pharma
Marketing

Stat­era Bio­phar­ma gets the OK to re­sume the study of a po­ten­tial stock­pile drug for lethal ra­di­a­tion ex­po­sure

4 years ago
FDA+
First page Previous page 615616617618619620621 Next page Last page
A service from the Financial Times